Siena Showcases Trastuzumab Deruxtecan Activity in HER2-Expressing mCRC
Salvatore Siena, MD, further discusses the DESTINY-CRC01 trial with trastuzumab deruxtecan and projects the impact of these findings on patients with HER2-expressing metastatic CRC.
Source: OncLive